Company intelligence / Profile preview
APTA Therapeutics
Berlin, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
APTA Therapeutics is a clinical-stage biopharmaceutical company that acquired rovunaptabin (formerly BC 007) from insolvent Berlin Cures after a Phase 2 trial in post‑COVID syndrome failed to meet its primary endpoint versus placebo; the company plans further, biomarker‑enriched clinical studies in post‑COVID syndrome and heart failure to identify responsive subgroups and advance the drug toward a potential Phase 3 registration study.[9][4][13]
- Therapeutic areas
- CardiovascularOphthalmologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Charité – Universitätsmedizin BerlinMax Delbrück Center for Molecular MedicineEye Clinic of Erlangen University Hospital
Beyond the preview
Go deeper on APTA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APTA Therapeutics.